Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
McKesson
Julphar
Cipla
US Army
Chubb
QuintilesIMS
Harvard Business School
Citi

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 3,927,046

« Back to Dashboard

Summary for Patent: 3,927,046
Title: Novel 11,11-alkylidene steroids
Abstract:The invention relates to novel 11,11-alkylidene steroids of the estrane and (19-nor-)pregnane series having a double bond starting from carbon atom 5, the alkylidene group in 11-position having the formula ##EQU1## wherein R.sub.1 and R.sub.2 are hydrogen or an alkyl group having 1-2 C-atoms, and to processes for their preparation. The novel compounds have very interesting biological activities, such as anabolic, androgenic, estrogenic, progestative, anti-androgenic, anti-oestrogenic, ovulation-inhibiting and gonad-inhibiting activities.
Inventor(s): van den Broek; Albertus Joannes (Oss, NL)
Assignee: Akzona Incorporated (Asheville, NC)
Application Number:05/420,823
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 3,927,046

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 3,927,046

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Netherlands7216767Dec 9, 1972
Netherlands7315704Nov 15, 1973

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Johnson and Johnson
McKesson
Farmers Insurance
Cantor Fitzgerald
Teva
Accenture
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.